	Analysis of Large Language Model Decision Making in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer. JCO Clin Cancer Inform Buonaiuto R, Caltavituro A, Di Rienzo R, Grieco A, Mangiacotti FP, Longobardi A, Cantile V, Molinaro V, Pagliuca M, Buono G, De Placido P, Pietroluongo E, Forestieri V, Martinelli C, di Lauro V, Leo L, D'Aiuto M, Bianchini G, Criscitiello C, Bianco R, Del Mastro L, De Laurentiis M, Arpino G, De Angelis C, Giuliano M. PMID: 41791000 [PubMed - in process]
	The effect of neoadjuvant therapy on radiological, surgical, and pathological results in nonmetastatic breast cancer: A retrospective observational study. Medicine (Baltimore) Çorapli M, Alaku. PMID: 41790702 [PubMed - in process]
	Clinicopathologic characteristics and survival outcomes of patients with high-grade neuroendocrine cervical cancer. Medicine (Baltimore) Chen X, Zheng X, Yang Z, Sui F, Han C, Lu C, Wang X, Kong W. PMID: 41790645 [PubMed - indexed for MEDLINE]
	Attitudes and Experiences of Patients Diagnosed With Ovarian Cancer During Chemotherapy: A Qualitative Systematic Review. Public Health Nurs Pan W, Zhuang J, Zhang X, Li B. PMID: 41789837 [PubMed - as supplied by publisher]
	Injectable etoposide-loaded dextran nanoparticles for â€Žbreast cancer treatment: physicochemical characterization, cytotoxicity â€Žstudies, macrophage activity, and gene expression profiling. Nanomedicine (Lond) Moni SS, Qadri MM, Moshi JM, Hawsawi YM, Alotaibi S, Riadi Y, Halawi HAA, Sultan MH, Salawi A, Kameli N, Mobarki AA, Kaabi MA, Rehman ZU, Elmobark ME, Aljahdali IA, Oraibi B, Shabaj HM, Jeraiby MA. PMID: 41789771 [PubMed - as supplied by publisher]
	Factors associated with intentional non-adherence to endocrine treatment among early breast cancer survivors: A multicenter cross-sectional study. Br J Clin Pharmacol Okro, Silovski T, Plaveti, Kifer D, Budisavljevi, Silovski H, Peri, Dra, Skelin M, Bru, Zlatovi, Mucalo I. PMID: 41789764 [PubMed - as supplied by publisher]
	Habitat radiomics based on CT for assessing BRCA mutation status in patients with high-grade serous ovarian cancer: a multicenter study. Front Oncol Zhang S, Yang H, Wang F, Wang H, Zou Y, Wang C, Jiao J, Yu X. PMID: 41788993 [PubMed]
	Circulating cell-free DNA as an integrative biomarker in breast cancer: correlation with molecular subtypes, mutation status, and treatment response. Front Oncol Solanki R, Kaur A, Gothwal R, Lakhera KK, Kalal BS, Vijay U. PMID: 41788987 [PubMed]
	Evaluating the effect of using a mobile app on the management of chemotherapy side effects and quality of life in breast cancer patients: Protocol for a randomized controlled trial. J Educ Health Promot Raei Mehneh M, Kimiafar K, Mousavi Baigi SF, Marouzi P, Shahidsales S, Sarbaz M. PMID: 41788960 [PubMed]
	Relationships between social support and resilience of breast cancer patients in Indonesia: A cross-sectional study. J Educ Health Promot Pulungan RM, Helda H, Wahyono TYM, Sutandyo N. PMID: 41788944 [PubMed]
	Correction: Adherence with hormonal therapy in women with breast cancer: a cross-sectional study in Medellin, Colombia. Colomb Med (Cali) PMID: 41788894 [PubMed - in process]
	Fusion of genomic and pathological data for breast cancer detection using BCDNN. Front Med (Lausanne) Bilal A, Obidallah WJ, Wassan S, Albathan M, Almakki R, Alshaikh Z, Shafiq M. PMID: 41788706 [PubMed]
	Factors Influencing Pathological Complete Response After Neoadjuvant Chemotherapy in Breast Cancer: A Single-Center Retrospective Study Focusing on ER and HER-2 Status. Int J Breast Cancer Zhang Y, Qiu S, Wang X. PMID: 41788672 [PubMed]
	An exploratory serum metabolomics study for screening and staging of breast cancer. Gynecol Endocrinol Zou Y, Song D, Cai Y, Liang K, Fu J, Zhang H. PMID: 41787748 [PubMed - in process]
	Cancer-immunity cycle-based molecular subtypes in breast cancer predict the response to immune checkpoint inhibitors. Cancer Biol Med Shao D, Yu T, Xiao Y, Shao Z. PMID: 41787716 [PubMed - as supplied by publisher]
	Long-term benefit from adjuvant tamoxifen therapy for ER+ HER2- breast cancer by PR positivity. Int J Cancer Nordenskjöld AE, Ríos-Romero M, Dar H, Fornander T, Perez-Tenorio G, Fohlin H, Stål O, Tutzauer J, Lindström LS. PMID: 41787605 [PubMed - as supplied by publisher]
	Genetically predicted inflammatory cytokines mediate the associations between the gut microbiota and ovarian cancer: a bidirectional two-sample Mendelian randomization study. J Ovarian Res Chuan L, Yao B, Zhang H, Luo S, Lu G, Wu Y, Ren Y. PMID: 41787531 [PubMed - as supplied by publisher]
	DNA methylation-regulated AKAP12 expression modulates ECM remodeling and ADP/FAD ratio to influence prognosis in ovarian cancer. J Ovarian Res Ying Y, Zhang H, Ming J, Yu L, Wang F, Guo Z. PMID: 41787475 [PubMed - as supplied by publisher]
	Acceptance and commitment therapy improves the quality of life of breast cancer patients by reducing helplessness: a randomized controlled trial. BMC Palliat Care Song W, Shari NI, Abdullah MFILB, Hussin HB, Zhang R, Mansor NS. PMID: 41787365 [PubMed - as supplied by publisher]
	IL3RA identified as novel biomarker and therapeutic target for ER(+) breast cancer through plasma proteome-wide mendelian randomization and TCGA database analysis. Clin Proteomics Mei H, Zhang Z, Jiang N, Lu W, Chang L, Song Q, Li F. PMID: 41787256 [PubMed - as supplied by publisher]

Articles 1 - 20 / 325248

Page 1 of 16263



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy